Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188
| Autor: | Waun Ki Hong, Monica B. Spaulding, Q. Scott Ringenberg, Karl Tornyos, Harold S. Ballard, Charles Williams, Clair M. Haakenson, Richard L. Edwards, Edward D. Crum, R. Jackson Forcier, Joseph F. O'Donnell, Walter B. Forman, Walter L. Eaton, Gerhard J Johnson, Richard L. Schilsky, Cornelius J. Cornell, Stanley Zucker, James Levine, Linda A. Baczek, Leo R. Zacharski, Charles S. Faulkner, Charles L. Hoppel, Francisco Robert, Thomas E. Moritz, F. R. Rickles |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Pathology Lung Neoplasms medicine.medical_treatment Malignancy Random Allocation Internal medicine medicine Carcinoma Cyclic AMP Humans Prospective Studies Phosphodiesterase inhibitor Chemotherapy Clinical Trials as Topic Lung business.industry Cancer Mopidamol Oncogenes medicine.disease Chemotherapy regimen Dipyridamole medicine.anatomical_structure Pyrimidines Colonic Neoplasms business medicine.drug |
| Zdroj: | Journal of the National Cancer Institute. 80(2) |
| ISSN: | 0027-8874 |
| Popis: | Mopidamol (RA-233), a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans. RA-233 plus chemotherapy was compared with chemotherapy alone in a 5-year double-blind trial involving 719 patients with advanced carcinomas of the lung and of the colon. RA-233 treatment was associated with a statistically significant prolongation of survival in patients with non-small cell lung cancer (N-SCLC) limited to one hemithorax and with reduction in mean plasma fibrogen concentration. RA-233 was not toxic. The favorable effects on survival could not be explained by any factor other than the RA-233 treatment. In other tumor categories tested, no differences in survival were observed. These results suggest that RA-233 is useful in the treatment of N-SCLC of limited extent. They also suggest that therapeutic intervention aimed at modified intracellular pathways might constitute a novel investigative approach to the treatment of cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|